Mycoplasma pneumonia in children
Conditions
Interventions
Control group:Conventional Western Medicine Treatment
Experimental group:Conventional Western Medicine Treatment Combined with Pediatric Pulmonary Heat Clearing Granules
Sponsors
Hangzhou First People's Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 14 Years
Inclusion criteria
Inclusion criteria: 1. Age (3-14) years old (including 3 and 14 years old), male or female not limited; Those who meet the diagnostic criteria for Mycoplasma pneumoniae pneumonia in Western medicine and test positive for Mycoplasma pneumoniae; 2. Meet the traditional Chinese medicine diagnostic and treatment criteria for Mycoplasma pneumoniae pneumonia in children (2023) and the "Diagnosis and Treatment Guidelines for Mycoplasma pneumoniae pneumonia in children (2025 edition)" for "wind heat closed lung syndrome", "phlegm heat closed lung syndrome", and "toxic heat closed lung syndrome"; 3. Those who have not received other relevant treatments; 4. The legal guardian of the subject voluntarily signs the informed consent form, and subjects aged >= 8 years are required to voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic to the test drug used in this study, erythromycin, any other macrolide antibiotic or ketone lactone antibiotic, or any excipient; 2. Excluding mixed bacterial infections; 3. Those with persistent cough symptoms for more than one week, or having chronic respiratory diseases; 4. Severely malnourished children, or children with other serious systemic diseases such as cardiovascular, liver, kidney (AST and ALT exceeding 1.5 times the upper limit of normal, Cr exceeding the upper limit of normal, urine protein ++ or more, heart muscle enzymes > 2 times the upper limit of normal, absolute neutrophil count < 1.0), hematological system, etc., and children with mental disorders; 5. Other lesions or conditions that, according to the investigator's judgment, reduce the possibility of enrollment, complicate the enrollment process, or affect the determination of therapeutic efficacy; 6. Children who have participated in other clinical trials within the past 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory factor levels;Adverse reaction;Imaging examination;Time of disappearance of symptoms and signs; | — |
Countries
China
Contacts
Public ContactJiang Chunming
Hangzhou First People's Hospital
Outcome results
None listed